SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a rare subgroup of lymphomas. This disease is predominantly found in older people and often has extranodal involvement including skin and soft tissues. To verify the diagnosis, it is necessary to perform histological and immunohistochemical tests, which show the expression of CD30 activation antigen in different proportions (less than 10 %, not more than 80 %) in addition to the expression of other T-cell antigens (CD2, CD4, CD5, CD7). When choosing the induction regimen in older people with relevant cardiac history, it is preferable to use non-anthracycline-containing chemotherapy courses. However, despite the low intensity of such regimens, treatment of elderly patients is associated with high risk of side effects. Using new drugs (monoclonal antibodies, epigenetic agents) in combination with polychemotherapy is a promising direction opening a possibility of successful management for all patients including those older than 65 years. In the described clinical case of PTCL-NOS, the patient had primary refractory disease. Significant clinical response (complete remission) was achieved as a result of targeted therapy with brentuximab vedotin containing anti-CD30 chimeric antibody conjugated to a microtubuledisrupting agent (monomethyl auristatin E) without toxicity and any infections. In case of ambiguous situation (an increase in the size of one of the tumor sites with regression of others, signs of infection – hyperemia, perifocal edema, the spread of the necrosis zone), histological verification is necessary to confirm the disease progression. 

1. Ellin F., Landström J., Jerkeman M. et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014,124(10):1570–7. DOI: 10.1182/blood-2014-04-573089.

2. De Leval L., Parrens M., Le Bras F. et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica 2015,100(9):e361–4. DOI: 10.3324/haematol.2015.126300.

3. Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016,127(20):2375–90. DOI: 10.1182/blood-2016-01-643569.

4. Weisenburger D.D., Savage K.J., Harris N.L. et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011,117(12):3402–8. DOI: 10.1182/blood-2010-09-310342.

5. Federico M., Rudiger T., Bellei M. et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 2013,31(2):240–6. DOI: 10.1200/JCO.2011.37.3647.

6. Mourad N., Mounier N., Brière J. et al. Clinical, biologic and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008,111(9): 4463–70. DOI: 10.1182/blood-2007-08-105759.

7. Yamashita Y., Nakamura S., Kagami Y. et al. Lennert's lymphoma: a variant of cytotoxic T-cell lymphoma? Am J Surg Pathol 2000,24(12):1627–33. PMID: 11117783.

8. Bossard C., Dobay M.P., Parrens M. et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral Tcell lymphomas: high correlation with mRNA levels. Blood 2014,124(19):2983–6. DOI: 10.1182/blood-2014-07-584953.

9. De Leval L., Bisig B., Thielen C. et al. Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol 2009,72(2):125–43. DOI: 10.1016/j.critrevonc.2009.01.002.

10. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М.: Буки Веди, 2016. С. 85–91. [Russian Clinical Guidelines for the Diagnosis and Treatment of Lymphoproliferative Diseases. Eds.: Poddubnaya I.V., Savchenko V.G. Moscow: Buki Vedi, 2016. P. 85–91. (In Russ)].

11. Zinzani P.L., Venturini F., Stefoni V. et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010,21(4):860–3. DOI: 10.1093/annonc/mdp508

12. Arkenau H.T., Chong G., Cunningham D. et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007,92(2):271–2. PMID: 17296587.

13. Park B.B., Kim W.S., Suh C. et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol 2015,94(11):1845–51. DOI: 10.1007/s00277-015-2468-y.

14. Schmitz N., Trümper L., Ziepert M. et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade NonHodgkin Lymphoma Study Group. Blood 2010,116(18):3418–25. DOI: 10.1182/blood-2010-02-270785.

15. Vose J., Armitage J., Weisenburger D. et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008,26(25):4124–30. DOI: 10.1200/JCO.2008.16.4558

16. Escalón M.P., Liu N.S., Yang Y. et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer 2005,103(10):2091–8. DOI: 10.1002/cncr.20999.

17. Kim J.G., Sohn S.K., Chae Y.S. et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006,58(1):35–9. DOI: 10.1007/s00280-005-0136-y.

18. Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL). In: ClinicalTrials.gov. [Internet]. [Cited 2017, March 31]. Available at: http://clinicaltrials.gov/show/ NCT01839097.

19. Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study. In: ClinicalTrials.gov [Internet]. [Cited 2017, March 31]. Available at: http://clinicaltrials.gov/show/NCT02223208.

20. Mahadevan D., Unger J.M., Spier C.M. et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013,119(2):371–9. DOI: 10.1002/cncr.27733.

21. Trumper L.H., Wulf G., Ziepert M. et al. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma of the elderly: final results of 116 patients treated in the international ACT-2 phase III trial. J Clin Oncol 2016,34:7500.

22. Anderson M.D. Cancer Center. Safety and Efficacy of Brentuximab Vedotin Maintenance After Allogeneic Stem Cell Transplantation in High Risk CD30+ Lymphoma (Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL). In: ClinicalTrials.gov [Internet]. [Cited 2017, March 31]. Available at: http:// clinicaltrials.gov/show/NCT02169505.

23. A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOPbased Chemotherapy. In: ClinicalTrials.gov [Internet]. [Cited 2017, March 31]. Available at: http://clinicaltrials.gov/show/ NCT01420679.

24. A Randomized, Double-blind, Placebocontrolled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas. In: ClinicalTrials.gov [Internet]. [Cited 2017, March 31]. Available at: http:// clinicaltrials.gov/show/NCT01777152.

25. Horwitz S.M., Advani R.H., Bartlett N.L. et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014,123(20):3095–100. DOI: 10.1182/blood-2013-12-542142.

26. A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC#749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL). In: ClinicalTrials.gov. [Internet]. [Cited 2017, March 31]. Available at: http://clinicaltrials. gov/show/NCT01979536.

27. Jo J.C., Choi Y., Shin H.J. et al. Peripheral T-cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). Ann Hematol 2016,95(4):619–24. DOI: 10.1007/s00277-016-2597-y.

28. Niitsu N., Kohori M., Higashihara M. et al. Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci 2007,98(1):109–12. DOI: 10.1111/j.1349-7006.2006.00349.x.